drugset / Trial / NCT06624228
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Timeline
- Start
- 2024-10-21
- Primary completion
- 2026-02-06
- Completion
- 2026-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimekizumab | Monoclonal antibody | — | — |
| Comparator | Risankizumab | Monoclonal antibody | — | — |